Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

A Clinical Experience Programme to Collect Data on the Safety and Efficacy of NovoMix® 30 in the Treatment of Patients With Type 2 Diabetes in Jordan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01542060

Enrollment

298

Registered

2012-03-01

Start date

2004-01-31

Completion date

2004-12-31

Last updated

2012-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.

Interventions

DRUGbiphasic insulin aspart 30

Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—

Secondary

Measure	Time frame
Incidence of hypoglycaemic episodes	—
FBG (Fasting Blood Glucose)	—
Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)	—
Incidence of adverse events	—

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026